CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer. Our lead candidate, CG0070, is a selective oncolytic immunotherapy which has completed a Phase 2 trial for the treatment of high-grade NMIBC after BCG failure. Additional indications in MIBC and other solid tumors are being pursued with CG0070 in combination with immune checkpoint modulators.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/14/20 | $47,000,000 | Series D |
Camford Capital Kissei Pharmaceutical  ORI Healthcare Fund Perseverance Capital Management | undisclosed |
| 11/15/22 | $120,000,000 | Series E |
Acorn Bioventures Ally Bridge Group Decheng Capital Longitude Capital Malin Corporation ORI Capital RA Capital Management Sirona Capital | undisclosed |
